Please use this identifier to cite or link to this item:
Title: Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2
Author: Kudo, Masatoshi
Galle, Peter R.
Llovet i Bayer, Josep Maria
Finn, Richard S.
Vogel, Arndt
Motomura, Kenta
Assenat, Eric
Merle, Philippe
Brandi, Giovanni
Daniele, Bruno
Okusaka, Takuji
Tomášek, Jiří
Borg, Christophe
Dadduzio, Vincenzo
Morimoto, Manabu
Pracht, Marc
Jen, Min-Hua
Widau, Ryan C.
Shinozaki, Kenta
Yoshikawa, Reigetsu
Zhu, Andrew X.
Keywords: Càncer de fetge
Anticossos monoclonals
Persones grans dependents
Liver cancer
Monoclonal antibodies
Frail elderly
Issue Date: Aug-2020
Publisher: John Wiley & Sons
Abstract: Background & Aims: Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH‐2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha‐fetoprotein (AFP) ≥400 ng/mL showed an overall ssurvival (OS) benefit for ramucirumab. These post‐hoc analyses examined efficacy and safety of ramucirumab in patients with HCC and baseline AFP ≥ 400 ng/mL by three prespecified age subgroups (<65, ≥65 to <75 and ≥75 years). Methods: Individual patient data were pooled from REACH (baseline AFP ≥400 ng/mL) and REACH‐2. Kaplan‐Meier and Cox proportional hazards regression methods (stratified by study) assessed OS, progression‐free survival (PFS), time to progression (TTP) and patient‐reported outcomes (Functional Hepatobiliary System Index‐8 [FHSI‐8] score). Results: A total of 542 patients (<65 years: n = 302; ≥65 to <75 years: n = 160; ≥75 years: n = 80) showed similar baseline characteristics between ramucirumab and placebo. Older subgroups had higher hepatitis C and steatohepatitis incidences, and lower AFP levels, than the <65 years subgroup. Ramucirumab prolonged OS in patients <65 years (hazard ratio [HR], 0.753; 95% CI 0.581‐0.975), ≥65 to <75 years (0.602; 0.419‐0.866) and ≥75 years (0.709; 0.420‐1.199), PFS and TTP irrespective of age. Ramucirumab showed similar overall safety profiles across subgroups, with a consistent median relative dose intensity ≥97.8%. A trend towards a delay in symptom deterioration in FHSI‐8 with ramucirumab was observed in all subgroups. Conclusions: In this post‐hoc analysis, ramucirumab showed a survival benefit across age subgroups with a tolerable safety profile, supporting its use in advanced HCC with elevated AFP, irrespective of age, including ≥75 years.
Note: Reproducció del document publicat a:
It is part of: Liver International, 2020, vol. 40, num. 8, p. 2008-2020
Related resource:
ISSN: 1478-3223
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
701026.pdf649.67 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons